Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.

"Conflict of interest PK is funded by the DFG Excellence grant to FP (DFG exc 257). FP received speaker honoraria and travel support by Bayer Healthcare, Teva, Sanofi-Aventis/Genzyme, Biogen Idec, Novartis, and Merck-Serono. FP serves on the scientific advisory board for Novartis; received speaker honoraria and travel funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an academic editor for PLoS ONE; is an associate editor for Neurology® Neuroimmunology & Neuroinflammation; consulted for SanofiGenzyme, Biogen Idec, MedImmune, Shire, and Alexion; and received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, and National Multiple Sclerosis of the USA. A.U. JD received a limited grant for clinical research on vitamin D by Bayer Healthcare, speaker honoraria by Bayer Healthcare, Novartis, Sanofi Genzyme, and Biogen, consultancy honoraria by Novartis, Merck Serono, Sanofi Genzyme, and Bayer Healthcare, and travel support by Merck-Serono, Biogen, Novartis, and Bayer Healthcare."

"Compliance with ethical standards: Conflict of interestPK is funded by the DFG Excellence grant to FP (DFG exc 257).FP received speaker honoraria and travel support by Bayer Healthcare, Teva, Sanofi-Aventis/Genzyme, Biogen Idec, Novartis, and Merck-Serono. FP serves on the scientific advisory board for Novartis; received speaker honoraria and travel funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an academic editor for PLoS ONE; is an associate editor for Neurology® Neuroimmunology & Neuroinflammation; consulted for SanofiGenzyme, Biogen Idec, MedImmune, Shire, and Alexion; and received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, and National Multiple Sclerosis of the USA. A.U.JD received a limited grant for clinical research on vitamin D by Bayer Healthcare, speaker honoraria by Bayer Healthcare, Novartis, Sanofi Genzyme, and Biogen, consultancy honoraria by Novartis, Merck Serono, Sanofi Genzyme, and Bayer Healthcare, and travel support by Merck-Serono, Biogen, Novartis, and Bayer Healthcare."